Contestabile Andrea, Magara Salvatore, Cancedda Laura
Department of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia (IIT) Genova, Italy.
Department of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia (IIT)Genova, Italy; Dulbecco Telethon InstituteGenova, Italy.
Front Cell Neurosci. 2017 Mar 7;11:54. doi: 10.3389/fncel.2017.00054. eCollection 2017.
Down syndrome (DS) is a genetic disorder caused by the presence of a third copy of chromosome 21. DS affects multiple organs, but it invariably results in altered brain development and diverse degrees of intellectual disability. A large body of evidence has shown that synaptic deficits and memory impairment are largely determined by altered GABAergic signaling in trisomic mouse models of DS. These alterations arise during brain development while extending into adulthood, and include genesis of GABAergic neurons, variation of the inhibitory drive and modifications in the control of neural-network excitability. Accordingly, different pharmacological interventions targeting GABAergic signaling have proven promising preclinical approaches to rescue cognitive impairment in DS mouse models. In this review, we will discuss recent data regarding the complex scenario of GABAergic dysfunctions in the trisomic brain of DS mice and patients, and we will evaluate the state of current clinical research targeting GABAergic signaling in individuals with DS.
唐氏综合征(DS)是一种由21号染色体三体导致的遗传性疾病。DS会影响多个器官,但必然会导致大脑发育改变和不同程度的智力残疾。大量证据表明,在DS的三体小鼠模型中,突触缺陷和记忆障碍很大程度上由GABA能信号改变所决定。这些改变在大脑发育过程中出现,并持续到成年期,包括GABA能神经元的发生、抑制性驱动的变化以及神经网络兴奋性控制的改变。因此,针对GABA能信号的不同药物干预已被证明是拯救DS小鼠模型认知障碍的有前景的临床前方法。在本综述中,我们将讨论关于DS小鼠和患者三体大脑中GABA能功能障碍复杂情况的最新数据,并评估目前针对DS个体中GABA能信号的临床研究状况。